INS-CLINICIAN ADMINISTER DRUG
SB1746 amends the Illinois Insurance Code to regulate how health plans and pharmacy benefit managers handle clinician-administered drugs, which are outpatient prescription drugs that generally must be given by a health care provider in a clinical setting rather than self-administered by the patient. For health benefit plans amended, delivered, issued, or renewed on or after January 1, 2026, the bill prohibits a plan or its contracted pharmacy benefit manager from steering enrollees to a selected pharmacy for these drugs, requiring transport of the drug to another site of service, imposing higher cost-sharing for using a nonselected provider or pharmacy, conditioning or denying coverage or reimbursement based on site of service, or otherwise restricting access to medically necessary clinician-administered drugs and related services. It also bars plans from requiring home infusion or specific pharmacy-benefit use for these drugs and prohibits providers from being blocked from billing for reimbursement.
The bill also requires clinician-administered drugs to comply with the federal Drug Supply Chain Security Act’s supply chain security and chain-of-distribution requirements. The Department of Insurance is given rulemaking authority to implement the new section. In addition to the Insurance Code, SB1746 amends the State Employees Group Insurance Act, Counties Code, Illinois Municipal Code, School Code, Health Maintenance Organization Act, and Voluntary Health Services Plans Act so that state, county, municipal, school, HMO, and health services plan coverage must comply with the new requirements.
The bill’s impact is to expand consumer protections and access standards for specialty and provider-administered prescription drugs across a broad range of Illinois-regulated health coverage. It would limit pharmacy benefit manager practices that direct patients to particular pharmacies or sites of care, and it would standardize coverage rules for public employee plans and other health plans subject to Illinois insurance law. Because the bill applies to plans renewed on or after January 1, 2026, it would affect future plan years rather than immediately changing existing contracts.
No committee transcripts or votes were provided, so there is no recorded legislative debate or roll-call history to gauge support or opposition. Based on the bill text alone, the measure appears aimed at protecting patient access and reducing utilization-management practices in specialty drug coverage, while potentially drawing concern from insurers and pharmacy benefit managers over reduced flexibility in network design, site-of-service management, and cost control. The main policy tension is between access to medically necessary treatment and the ability of plans to steer drug dispensing and administration to lower-cost channels.
SB1746 would add a new Section 356z.26a to the Illinois Insurance Code and then incorporate that requirement into multiple other statutes governing public and quasi-public health coverage. It would apply to health benefit plans and related coverage arrangements, including state employee, county, municipal, school, HMO, and voluntary health services plan coverage, thereby creating a statewide rule against certain pharmacy benefit manager and insurer practices for clinician-administered drugs. The Department of Insurance would gain enforcement and rulemaking authority, and the bill would take effect for plans renewed on or after January 1, 2026.
No votes or committee testimony were provided, so there is no documented public sentiment from the legislative record included here. The bill’s structure and findings language suggest a pro-consumer, access-oriented purpose, emphasizing safe and effective drug therapy and limiting plan interference with provider-administered medications. The likely supportive view is that the bill protects patients and providers from restrictive PBM practices, while the likely skeptical view is that it constrains insurers’ and PBMs’ ability to manage costs and direct care.
The central point of contention is the bill’s restriction on pharmacy benefit managers and health plans from steering clinician-administered drugs to selected pharmacies or sites of service, imposing differential cost-sharing, or conditioning reimbursement on where the drug is obtained or administered. Supporters would likely argue these practices can delay care, burden patients, and interfere with medically necessary treatment. Opponents would likely argue that the bill limits utilization management, reduces negotiating leverage, and may increase costs for plans and enrollees. Another possible issue is the breadth of the bill’s application across public employee and local government plans, which could raise administrative and cost concerns for affected plan sponsors.